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Increasing the efficacy of approved systemic treatments in metastasized pancreatic 
neuroendocrine tumors (PanNETs) is an unmet medical need. The anti-angiogenic tyrosine 
kinase inhibitor sunitinib is approved for PanNET treatment. Additionally, sunitinib is a 
lysosomotropic drug and such drugs can induce lysosomal membrane permeabilization as 
well as autophagy. We investigated sunitinib-induced autophagy as a possible mechanism of 
PanNET therapy resistance. Sunitinib accumulated in lysosomes and induced autophagy in 
PanNET cell lines. Adding the autophagy inhibitor chloroquine reduced cell viability in cell 
lines and in primary cells isolated from PanNET patients. The same treatment combination 
reduced tumor burden in the Rip1Tag2 transgenic PanNET mouse model. The combination 
of sunitinib and chloroquine reduced recovery and induced apoptosis in vitro, whereas single 
treatments did not. Knockdown of key autophagy proteins in combination with sunitinib 
showed similar effect as chloroquine. Sunitinib also induced lysosomal membrane 
permeabilization, which further increased in the presence of chloroquine or knockdown of 
lysosome-associated membrane protein (LAMP2). Both combinations led to cell death. Our 
data indicate that chloroquine increases sunitinib efficacy in PanNET treatment via 
autophagy inhibition and lysosomal membrane permeabilization. We suggest that adding 
chloroquine to sunitinib treatment will increase efficacy of PanNET treatment and that such 
patients should be included in respective ongoing clinical trials.  
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Pancreatic neuroendocrine tumors (PanNETs) show a neuroendocrine differentiation 
analogous to the cells of islets of Langerhans and represent 3% of pancreatic tumors. 
PanNETs have significant malignant potential and surgery is the only curative option. Despite 
increasing availability of therapy options, stable disease is achieved in only 30% of stage IV 
PanNET patients and partial remission is observed only in rare cases (1-4). Sunitinib is a 
multi-tyrosine kinase inhibitor targeting mainly vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF) receptors leading to inhibition of angiogenesis and 
destabilization of existing vasculature (5). Sunitinib has a dual anti-tumor effect in PanNETs 
targeting the vasculature as well as targeting tyrosine kinases expressed by tumor cells (6,7). 
Sunitinib is approved for treatment of advanced PanNETs and has been shown to prolong 
progression free survival (4). However, its efficacy is limited by intrinsic and acquired 
resistance. In Rip1Tag2 mice, a transgenic mouse model for PanNETs, mechanisms of 
acquired resistance towards sunitinib have been described (8-10). Sunitinib is a 
lysosomotropic drug, which freely diffuses the lysosomal membrane.  In the lysosome, it is 
protonated due to the low pH, and thus accumulates due to the inability to diffuse through the 
membrane (11). Ellegaard et al. have shown that sunitinib inhibits acid sphingomyelinase 
(ASM), which influences lysosome stability (12). Sunitinib further leads to lysosomal leakage 
and later to mitochondrial membrane permeabilization and ultimately to cell death (12). 
Interestingly, cancer cell lysosomes are less stable than normal lysosomes due to 
transformation-associated changes in lysosome-associated membrane protein 1 (LAMP1) 
and LAMP2 levels as well as in sphingolipid metabolism (13-15). Lysosomotropic drugs were 
shown to trigger lysosomal cell death even in apoptosis- and multidrug-resistant cancer cells 
(15). Therefore, targeting lysosomes is considered a promising yet rather unexplored 
therapeutic strategy. More recently, it has been proposed that leaky lysosomes do not 
necessarily lead to cell death. Instead, the release of lysosomal enzymes might affect 
physiological functions, for example influencing invasion by degradation of focal adhesions 
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(16). Additionally, lysosomes undergoing lysosomal membrane permeabilization (LMP) 
induce autophagy and are subsequently cleared by lysophagy (17-19).  
Macroautophagy, hereafter named autophagy, is mainly a cell survival mechanism activated 
upon cellular stress to sequester and degrade long-lived proteins and damaged organelles 
and to recycle nutrients (20). Autophagy can promote tumorigenesis by increasing cell 
survival in unfavorable environment such as hypoxia or anti-cancer treatments (21). Many 
anti-cancer treatments have been shown to affect autophagy in vitro and in vivo. Previously, 
it was found that sunitinib modulates autophagy in other cellular systems in vitro (22-25). 
However, whether the modulation of autophagy by sunitinib is due to a block or an induction 
of autophagy is controversial. Since autophagy can promote tumorigenesis and resistance 
towards anti-cancer treatments, it has been exploited as therapeutic target in vitro, in vivo 
and in early clinical trials. In clinical trials, the most commonly used treatments to inhibit 
autophagy are the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ) (26). 
Both are lysosomotropic compounds, which inhibit autophagy via blocking lysosomal 
function. The role of autophagy and response towards its inhibition depends on tumor stage. 
Indeed autophagy functions are initially often tumor suppressing and at later stages tumor 
promoting. Additionally, the role of autophagy differs between tumor types (21). The role of 
autophagy role in mediating sunitinib response has not been studied in PanNET yet.  
In this study, we investigated whether sunitinib upregulates autophagy in PanNETs and 
whether this is important in mediating therapy response or resistance. We assessed whether 
combination with the autophagy inhibitor chloroquine enhanced the anti-tumor effect of 
sunitinib. Moreover, we questioned how sunitinib accumulation in lysosomes and LMP affect 
autophagy and treatment response. 
Material & Methods 
Drugs, inhibitors and antibodies 
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Bafilomycin A1 (B-1080) was purchased from LC Laboratories, chloroquine (C6628) from 
Sigma, and sunitinib (S1042) from Selleckchem. 
Antibodies against ATG5 (#2630), cleaved caspase 3 (#9661 and #9664), cleaved PARP 
(#9541) were purchased from Cell Signaling, ATG7 (ab52472) and CD31 (ab28364) from 
Abcam, galectin 3 (#556904) from BD Biosciences, GAPDH (#MAB374, clone 6C5) from 
Millipore, LAMP2 (sc-18822) and SV40 (sc-20800) from Santa Cruz, Ki67 (#RM-9106) from 
Thermo Fisher Scientific and LC3B (NB600-1384) from Novus Biologicals. 
Cell lines 
BON1 cell line was provided by E.J. Speel, Maastricht, Netherlands in 2011. QGP1 cell line 
was purchased from the Japanese Health Sciences Foundation, Osaka, Japan in 2011. 
Short tandem repeat (STR) analysis by PCR was performed for both cell lines (QGP1 in 
2011 and 2016, BON1 in 2014 and 2016). QGP1 cells were authenticated. A BON1 profile 
does not exist yet but the profile of these cells did not match any known profile of cancer cell 
lines thus excluding contamination from other lines. Additionally, expression of the specific 
neuroendocrine markers chromogranin A and synaptophysin were routinely tested by 
immunohistochemistry. BON1 cells were cultured in DMEM/F12 medium (Sigma), QGP1 
cells in RPMI 1640 medium (Sigma). For both cell lines medium was supplemented with 10% 
FBS, 100U/ml penicillin and 0.1mg/ml streptomycin and cells were kept in a humidified 
incubator at 5%CO2 and 37°C. After thawing, cells were cultured for approximately two 
months. 
Generation of knockdown cell lines 
Short-hairpin RNA (shRNA) against ATG5 (NM_004849.1-420s1c1, NM_004849.1-915s1c1, 
NM_004849.1-1170s1c1), ATG7 (NM_006395.1-268s1c1, NM_006395.1-491s1c1, 
NM_006395.1-2173s1c1) and LAMP2 (NM_002294.1-291 and NM_002294.1-561) as well as 
a non-targeting shRNA control (SHC002) were delivered with a lentivirus expressing vector 
pLKO.1 (all from Sigma, MISSION shRNA). Lentivirus production and transduction were 
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performed as described (27). Cells were selected with 1.5µg/ml puromycin for 3-4 days. 
Knockdown efficiency was validated by immunoblotting of respective proteins. 
Primary cell culture 
Fresh human PanNET tissue was obtained from patients who underwent surgery at the 
Inselspital Bern and have signed an institutional informed consent. Ethical approval was 
given by the cantonal authorities (Kantonale Ethikkommission Bern, Ref.-Nr. KEK-BE 
105/2015). Fresh tissue was digested with collagenase IV (Worthington) and trypsin for 1h at 
37°C followed by red blood lysis with ACK buffer (Gibco). Single cell suspension was plated 
in 96-well plates and viability was measured after 48h treatment with ATPlite assay kit 
(Perkin Elmer) according to manufacturer instructions. Protein extracts were collected from 
96-well plates using urea lysis buffer (8M urea, 0.5% Triton X-100) and immunoblotting was 
performed as described. Primary tumor was from a male stage II patient (age 62, patient I) 
with a well-differentiated grade G2 tumor showing no hormone secretion. Liver metastasis 
was from a male stage IV patient (age 65, patient II), with a well-differentiated grade G3 
tumor showing no hormone secretion. Despite sunitinib is currently only approved for 
treatment of G1 and G2 tumors, patient II was included in this study due to the well-
differentiated state of the tumor. The coefficient of drug interaction (CDI) was calculated as 
CDI=AB/(AxB). AB is the relative viability after the combination treatment of drugs A and B, 
while A and B are the relative viability after single treatment with drug A and B, respectively. 
CDI<1 indicates a synergistic effect, CDI=1 an additive effect and CDI>1 an antagonistic 
effect (28). 
MTT and clonogenic assay 
Cells were cultured and treated in 96-well plates. To perform the MTT assay, cells were 
incubated with medium plus MTT (0.5mg/ml) at 37°C for 30-45min. Medium was removed 
and cells were lysed in DMSO. Sorensen solution (0.1M glycine, 0.1M NaCl, pH 10.5 in 
water) was added and absorbance measured at 570nm. For the clonogenic assay, cells were 
trypsinized after 72h of treatment and re-plated at equal numbers in 6-well plates. Colonies 
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were allowed to grow for two weeks in normal growth medium followed by fixation and 
staining of the colonies with 0.05% crystal violet in 30% ethanol. Colony numbers were 
measured with ColCount (Oxford Optronix). 
Long-lived protein degradation assay 
Cells were seeded in 24-well plates, radiolabeled with 0.1µCi 14C-valine per mL (L-[U-14-C] 
valine; code CFB.75, Amersham) for 48h and treated with sunitinib for 24h. Remaining 14C-
valine was removed and cells were incubated for 1h in medium supplemented with 10mM L-
valine. During this incubation time short-lived proteins were degraded. After washing, cells 
were incubated with medium supplemented with 10mM L-valine and with or without BafA1 for 
5.5h, in which long-lived proteins were degraded. Supernatant and trypsinized cells were 
collected and acid precipitation and centrifugation were performed to separate supernatant 
and pellet. Fractions were mixed with Microscint40 and radioactivity was measured by liquid 
scintillation counting. Percentage of proteolysis of long-lived proteins was calculated from 
supernatant and pellet fractions. 
Immunoblotting & Immunofluorescence 
Cells were lysed in urea buffer (8M urea, 0.5% Triton X-100) supplemented with protease 
inhibitors (Roche). 40-60µg of protein was loaded on a 12% SDS-PAGE gel (Biorad) and 
then transferred to a PVDF membrane (Biorad). Incubation with primary antibodies was 
performed overnight at 4°C, followed by washing steps and incubation with secondary 
antibodies (DyLight 650 conjugate goat anti-rabbit and DyLight 550 conjugate goat anti-
mouse, ImmunoReagents and Peroxidase-conjugated AffiniPure donkey anti-rabbit and 
donkey anti-mouse, Jackson ImmunoResearch) for 1h at room temperature. 
Chemiluminescent or fluorescent signal was detected using ChemiDoc MP System (Biorad). 
Total protein expression for quantification of specific protein expression was measured by 
use of the stain-free gel technology and imaged with the Chemidoc MP System (29). 
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For immunofluorescence, cells were plated on poly-L-lysine coated coverslips and treated for 
24-48h. Fixation and immunofluorescence for galectin 3 was performed as described.(30) As 
secondary antibody goat anti-mouse Alexa Fluor 568 conjugate (Invitrogen) was used. 
Analysis was performed at a microscope Zeiss Axioplan 2 at x40 magnification. Samples 
were blinded and percentage of positive cells was calculated from 500-600 counted cells on 
randomly chosen fields in the DAPI channel. 
Lysotracker staining 
Cells were incubated in coated glass-bottom plates and treated with sunitinib for 72h. 
Medium was replaced by medium containing 100nM Lysotracker Red DND-99 (L7528, 
Molecular Probes) and cells were incubated for 1h at 37°C. Medium was exchanged to 
normal medium and cells were imaged at a confocal microscope Olympus FluoView-1000 at 
x63 magnification.  
In vivo experiments 
Rip1Tag2 (C57BL/6) mice were kindly provided by G. Christofori, Basel, Switzerland. All 
experimental protocols were reviewed and approved by the Cantonal Veterinary Office of 
Bern (Switzerland). Mice were fed with food enriched in glucose starting from 10 weeks of 
age. Rip1Tag2 mice were treated daily from week 10 of age with 40mg/kg sunitinib p.o., 
50mg/kg chloroquine i.p. or the respective vehicle control for three weeks. Animals were 
monitored daily. At 13 weeks of age, animals were euthanized, tumor number (>1mm) and 
size was measured, and tissues were fixed in formalin overnight and embedded in paraffin. 
Tumor volume was calculated using the formula V=0.52*(width2)*length to estimate the 
volume of a sphere (31). Tumor volume per mouse was calculated as the sum of single 
tumors.  
Immunohistochemistry  
For immunohistochemistry (IHC) and TUNEL (TdT-mediated dUTP nick end labeling) on 
mouse pancreas, tissues were cut in 4µm thick serial sections followed by deparaffinization, 
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rehydration and antigen retrieval using an automated immunostainer (Bond RX, Leica 
Biosystems). Antigen retrieval was performed for LC3B with Tris for 30 minutes at 95°C, for 
Ki67, SV40 and CD31 with citrate for 30 minutes at 95°C. Antibodies were diluted as follows: 
LC3B 1:4000, Ki67 1:400, SV40 1:100, CD31 1:100. For TUNEL, slides were incubated with 
TdT enzyme (Promega) for 20 minutes. Slides were counterstained with haematoxylin and 
eosin (H&E). For liver metastasis assessment, four step sections of 75µm were cut from liver 
tissue and stained with SV40 as described above. Number of metastasis was counted and 
summarized from all sections. Microvessel density (MVD) was evaluated by a staff 
pathologist (A.B.) based on IHC for CD31 and classified as high or low. Classification of 
tumors was performed based on H&E staining and according to classification criteria defined 
by Lopez and Hanahan (32). Necrosis was evaluated by a staff pathologist (A.B.) based on 
H&E staining, as percentage of area showing pre-necrotic condensed nuclei (regional cell 
death) and necrosis (geographic necrosis) compared to total tumor volume. Representative 
pictures of analyses for classification and necrosis on H&E staining are shown in 
supplementary figures S1A and S1B, respectively. Proliferation was measured as 
percentage of Ki67-positive cells compared to tumor volume in all tumors > 1mm and 
average per mouse is shown. Number of TUNEL-positive cells was counted in one high-
power field chosen in the area of highest labeling. Autophagy was assessed by IHC for 
LC3B, classified according to the abundance and number of LC3B punctae, representative of 
autophagosomes (33). Mice were classified as either LC3B punctae low or LC3B punctae 
high. IHC for LC3B on 30 matched samples of human primary PanNET and liver metastasis 
(patient collective II as reported (34)) was performed as described above. Tumors were 
classified based on the abundance and number of LC3B punctae in absent, low or high 
LC3B punctae. 
Statistical analysis 
Statistical analyses were performed with GraphPad Software. Unpaired or paired t-test was 
used to compare groups. Contingency tables were analyzed using Fisher’s exact test. 
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Sample size (n) refers to biological replicates unless otherwise stated. * p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001. 
Results 
Sunitinib upregulates autophagy in PanNET cell lines and primary cells 
We assessed sunitinib effects on autophagy in PanNET cell lines by immunoblotting for 
microtubule associated protein 1 light chain 3B (MAP1LC3B/LC3B). The cytosolic form 
LC3B-I is lipidated to LC3B-II, which is incorporated into autophagosomes and represents 
autophagosome numbers. Sunitinib treatment alone increased LC3B-II levels in both BON1 
and QGP1 cells. To measure the autophagic flux we co-treated the cells with the lysosomal 
autophagy inhibitors chloroquine (CQ) or bafilomycin A1 (BafA1) (35), which block the fusion 
of autophagosomes with lysosomes via elevation of lysosomal pH. In both cell lines, LC3B-II 
levels further increased upon combination treatment of suntinib and autophagy inhibitors 
compared to single treatments alone, indicating increased autophagic flux. The effect was 
more prominent with CQ (Fig. 1A). Autophagy was also monitored by long-lived protein 
degradation assay (LLPDA) (20). Sunitinib increased autophagy-specific proteolysis in both 
cell lines (Fig. 1B, supplementary Fig. S2A). We assessed basal levels of autophagy in 
PanNET human tissue by immunohistochemistry for LC3B. LC3B punctae, representative for 
autophagosomes, significantly increased in liver metastasis compared to matched primary 
tumors, potentially indicating high levels of autophagy in stage IV patients (Supplementary 
Fig. S2B).  Importantly, also in primary cells freshly isolated from PanNET patients, sunitinib 
increased LC3B-II levels, which were further elevated with autophagy inhibition (Fig. 1C). In 
conclusion, sunitinib upregulates autophagy in PanNET cell lines and primary cells as 
measured by LC3B-II and proteolysis of long-lived proteins.  
Reduced viability and recovery upon combination with autophagy inhibition 
We hypothesized that sunitinib-induced autophagy may provide a pro-survival mechanism 
limiting sunitinib anti-tumoral effect and that combination with autophagy inhibitors might 
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have a beneficial effect in reducing cell viability. To address this hypothesis, we combined 
increasing doses of sunitinib with fixed concentrations of CQ and BafA1, the latter two not 
affecting cell viability (Fig. 1D). Sunitinib decreased BON1 and QGP1 cell viability in a dose-
dependent manner. The effect on viability was similar in both cell lines and seemed to be 
independent of target receptor expression levels (Supplementary Fig. S3A and S3B). CQ 
further reduced cell viability when combined with 10µM sunitinib (Fig. 1D, Supplementary 
Fig. S3A). Further experiments in the cell lines were performed with these concentrations of 
sunitinib and CQ. In primary cells from two PanNET patients, both sunitinib and CQ 
decreased viability in a dose-dependent manner. Also in primary PanNET cells their 
combination led to an increased effect (Fig. 1E). Calculation of the coefficient of drug 
interaction (CDI) as described previously (28) indicated an additive effect of sunitinib and CQ 
treatment in patient I (CDI=1.01) and a trend towards a synergistic effect in patient II 
(CDI=0.83).   Cell cycle analysis by FACS revealed that sunitinib induced a G1 cell cycle 
arrest in PanNET cell lines, while the cell cycle was not affected by CQ (Supplementary Fig. 
S3C). To assess the long-term effect and recovery from treatments a colony formation assay 
was used. Sunitinib combined with autophagy inhibition led to a significant 50% reduction in 
colony numbers (Fig. 1F).  
Reduced tumor burden in vivo upon combination treatment 
We next assessed if autophagy inhibition increases the anti-tumoral effect of sunitinib in vivo 
in Rip1Tag2 mice, a transgenic mouse model of PanNET. We started treatment of mice at 10 
weeks of age, when tumors have developed and can be detected macroscopically (Fig. 2A).  
Mice were treated for three weeks with either vehicle, CQ (50 mg/kg, daily i.p.), sunitinib (40 
mg/kg, daily p.o.) or a combination thereof (Figure 2A). A dose of 50 mg/kg CQ corresponds 
to the human equivalent dose of 250 mg, which is the starting dose of Phase I trials of CQ 
and HCQ in cancer (36,37). Fifty mg/kg CQ led to an increase of LC3 in a melanoma 
xenograft model and to intratumoral concentrations of CQ, which blocked autophagy 
efficiently in vitro (38). Tumor number was significantly reduced after combination treatment 
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compared to single treatments (sunitinib p=0.0045, CQ p=0.0480). Tumor volume was 
reduced by 50% after combination treatment compared to single treatments (sunitinib 
p=0.0527, CQ p=0.0050) (Fig. 2A). Importantly, tumor number and volume significantly 
increase during sunitinib treatment compared to the start at 10 weeks of age, but not during 
the combination treatment (Fig. 2A). Microvessel density was clearly reduced upon sunitinib 
and combination treatment and unchanged upon CQ treatment (Supplementary Fig. S4A). 
Proliferation did not change upon CQ treatment but decreased significantly with sunitinib 
(p=0.0224) and the combination treatment (p=0.0017) compared to vehicle treatment (Fig. 
2B and 2C). In addition to reduced proliferation, necrosis was elevated in tumors treated with 
sunitinib (p=0.0005) or sunitinib and CQ (p=0.0003) compared to vehicle-treated tumors (Fig. 
2D). The number of TUNEL-positive cells increased significantly upon sunitinib (p=0.0222) 
and the combination (p=0.0163) treatment (Fig. 2E, supplementary Fig. S4B). Tumor 
classification revealed that invasiveness decreased upon sunitinib and combination 
treatment (Supplementary Fig. S4C), while incidence of metastasis and number of 
metastases per mouse did not change (Supplementary Fig. S4D). Punctate LC3B positivity 
by immunohistochemistry was classified into low and high. The distribution of LC3B punctae 
low versus LC3B punctae high increased towards LC3B punctae high in single and 
combination treatments compared to vehicle (Fig. 2F), indicating an upregulation of 
autophagy by sunitinib also in vivo. In summary, combination treatment of suntinib and CQ 
leads to an increased anti-tumor effect compared to single treatments in a pre-clinical setting. 
Beneficial effect of combination treatment is partially due to autophagy inhibition 
To prove a direct role of autophagy in limiting sunitinib anti-tumoral effect we knocked down 
key autophagy proteins, autophagy-related protein 5 (ATG5), autophagy-related protein 7 
(ATG7) and lysosome-associated membrane protein 2 (LAMP2) by lentiviral delivery of 
shRNA. ATG5 and ATG7 are involved in vesicle formation and lipidation of LC3, while 
LAMP2 is a glycoprotein localized on the lysosome membrane, which is involved in the 
fusion between autophagosome and lysosome as well as in chaperone-mediated autophagy. 
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Upon knockdown, protein levels and starvation-induced autophagic flux were both reduced 
(Supplementary Fig. S5A-D). Proliferation and colony formation were slightly reduced in cells 
with shATG5, shATG7 or shLAMP2 compared to control-transduced cells (Fig. 3B and 4B). 
Cells with shATG5 and shATG7 had reduced viability upon sunitinib treatment compared to 
control-transduced cells (Fig. 3A). Additionally, recovery of sunitinib-treated shATG5 and 
shATG7 cells was significantly reduced compared to control-transduced cells to a similar 
extent as observed with the combination of sunitinib and CQ (Fig. 3B and 3C). While neither 
sunitinib nor the autophagy inhibitors CQ and BafA1 alone induced apoptosis in BON1 cells, 
their combination led to cleavage of caspase 3 and poly ADP ribose polymerase (PARP) 
(Fig. 3D, supplementary Fig. S6A and S6B). Sunitinib treatment did not induce apoptosis in 
BON1 ATG5 knockdown cells, whereas in QGP1 cells knocking down ATG5 already induced 
apoptosis, which was further increased by sunitinib treatment. In both cell lines, sunitinib 
treatment of ATG7 knockdown cells induced apoptosis, but at lower levels compared to 
pharmacological inhibition of autophagy (Fig. 3D and 3E). In summary, knockdown of early 
autophagy genes ATG5 and ATG7 only partially phenocopied the effect observed with 
pharmacological inhibitors. 
Interestingly, knockdown of the late autophagy gene LAMP2 better recapitulated the effect of 
pharmacological inhibition. Sunitinib treatment reduced viability of shLAMP2 cells compared 
to control-transduced cells (Fig. 4A) as well as cell recovery similarly to the combination 
treatment of sunitinib and CQ (Fig. 4B and 4C). Sunitinib treatment of shLAMP2 BON1 and 
QGP1 cells induced apoptosis to a level comparable or even stronger than combination with 
autophagy inhibitors (Fig. 4D and 4E). The strong effect observed on apoptosis upon 
sunitinib and LAMP2 knockdown compared to ATG5 and ATG7 knockdown prompted us to 
investigate closer the involvement of lysosomes in sunitinib mediated autophagy induction.  
Effect of combination treatment depends on lysosome stability and is mediated by 
lysosomal membrane permeabilization 
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LAMP2 has been shown to contribute to lysosomal stability (14). Knockdown of LAMP2 
sensitized BON1 and QGP1 cell lines towards CQ (Fig. 5A-C) and the sensitivity towards CQ 
seemed to be dependent on LAMP2 levels. BON1 cells with lower levels of LAMP2 were 
more sensitive to CQ than QGP1 (Fig. 5A-C). Based on these results we hypothesized that 
lysosomal stability is an important factor in the response towards sunitinib and chloroquine 
treatment. Sunitinib and chloroquine are both lysosomotropic drugs, which due to their 
structure accumulate in lysosomes (11). We confirmed the lysosomotropic property of 
sunitinib by demonstrating that it co-localized with Lysotracker Red in BON1 and QGP1 cells 
(Fig. 5D). Lysosomotropic drugs can induce lysosomal membrane permeabilization (LMP) 
leading to release of lysosomal content in the cytoplasm, which in turn can activate apoptosis 
(39-42), and autophagy (17-19). Immunofluorescence for galectin 1 or 3 is considered the 
gold standard for detecting LMP (19). Upon permeabilization of lysosomes, galectins 
translocates from the cytoplasm and bind to the glycocalyx in lysosomes, which can be 
detected by immunofluorescence as a dot-like staining (Fig. 5E). CQ alone did not induce 
LMP, while sunitinib alone significantly induced LMP after 48h treatment, quantified as 
percentage of galectin 3 positive cells. Combination treatment of BON1 cells with sunitinib 
and CQ significantly increased LMP after 24h and 48h (Fig. 5F). Accordingly, sunitinib-
treated shLAMP2 cells showed a significant increase of LMP and to the same degree as 
observed in control-transduced cells treated with sunitinib and CQ (Fig. 5G). Together, our 
data indicates that reduction of lysosomal stability, as in shLAMP2 cells or upon combination 
of the lysosomotropic drugs sunitinib and CQ, promotes LMP-induced damage, which then 
triggers apoptosis. 
Discussion 
Options for anti-cancer therapy are limited for patients with stage IV PanNETs. Since 2011, 
sunitinib has been approved for treatment of advanced PanNETs but it has a limited efficacy 
(4). Here we investigated if autophagy is involved in resistance to suntinib and therefore 
could be a potential therapeutic target. We evaluated our hypothesis on the only two 
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PanNET cell lines available, although these cell lines only partially represent PanNET biology 
(43,44). However, no better in vitro PanNET model is currently available. Due to this 
limitation, we studied our hypothesis additionally in primary cells from two PanNET patients 
and in vivo in a well-studied transgenic mouse model of PanNET. In PanNET cell lines and a 
transgenic PanNET mouse model we demonstrated that sunitinib combined with the 
autophagy inhibitor CQ has a significantly enhanced anti-tumor effect compared to single 
treatment alone. Additionally, the beneficial effect of the combination treatment was 
confirmed in human primary cell culture, suggesting that these findings might be relevant for 
PanNET patients. 
First, we showed that sunitinib increases autophagy in vitro in PanNET cell lines, in cells 
isolated from human PanNET tumors and in vivo in the Rip1Tag2 transgenic PanNET mouse 
model. Sunitinib alone led to an upregulation of LC3B-II levels corresponding to an increased 
number of autophagosomes in PanNET cell lines and primary cells. LC3B-II levels further 
elevated when autophagy was blocked with lysosomal inhibitors indicating increased 
autophagic flux. In vivo, the number of mice with high LC3B punctate staining, representative 
for autophagosomes, increased upon sunitinib. Previous studies on other tumor types in vivo 
and in patient samples also reported modulation of autophagy upon sunitinib treatment 
(45,46). In tumors, autophagy might be influenced by additional factors, which may also 
result from sunitinib’s anti-angiogenic activity, such as hypoxia (47), and inflammation or 
acidosis (48,49). These can be only partially mimicked in vitro. To our knowledge autophagy 
has not been assessed in human PanNET yet. We showed by immunohistochemistry for 
LC3B that autophagy is present in PanNETs with increased levels in liver metastasis 
compared to primary tumors, suggesting autophagy as a potential target in stage IV patients. 
We observed reduced cell recovery and induction of apoptosis in cell lines treated with the 
combination of sunitinib and CQ. Similarly, Eng et al. have shown a synergistic effect of 
sunitinib and CQ in reducing cell proliferation in a lung adenocarcinoma cell line (50). 
Combination of sunitinib with CQ in the Rip1Tag2 model led to an increased anti-tumoral 
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effect compared to single treatments alone, as measured by reduced tumor burden, reduced 
proliferation and increased necrosis. Importantly, tumor burden increased during sunitinib 
treatment compared to the start of the treatment, but did not during combination treatment, 
indicating that the combination treatment strongly impairs tumor development. All the 
sunitinib-treated tumors were less vascularized, however, there was no difference in CD31 
staining upon combination with CQ. This suggests that the increased anti-tumoral effect by 
the combination therapy is not explained by an effect on angiogenesis, but rather due to a 
direct effect on the cancer cells. Indeed, sunitinib has been shown to reduce tumor cell 
proliferation in vitro (23,24,50). 
Sunitinib treatment reduced histological signs of tumor invasiveness but the incidence and 
number of liver metastasis remained unchanged. Reported data on sunitinib-induced 
invasiveness and metastasis in the Rip1Tag2 model are however inconsistent. Sunitinib has 
been shown to lead to increased invasiveness and incidence of metastasis (8,9), while a 
recent publication reports no change in invasiveness and number of metastasis per mouse 
upon sunitinib treatment (51). One important difference among these studies including ours 
is the age of the mice and the duration of the treatment, which might affect invasiveness and 
metastasis formation. A possible genetic drift of the Rip1Tag2 mice after breeding in different 
laboratories for a long time might be another reason for the different results (51,52). In 
summary, our findings show an anti-tumor effect of the combination treatment in vivo.  
Sunitinib combined with ATG5 or ATG7 knockdown resulted in little or almost no apoptosis 
activation, while sunitinib combined with lysosome-targeting autophagy inhibitors such as 
CQ, BafA1 or LAMP2 knockdown, induced apoptosis. Our data suggest that lysosomes are 
centrally involved in the combination effect of sunitinib and CQ. This is in agreement with 
other studies showing that sunitinib as well as CQ and LAMP2 knockdown destabilize 
lysosomes (12,14,40). Destabilization of lysosomes can lead to lysosomal membrane 
permeabilization (LMP), which in turn can trigger cell death or autophagy (17-19). In BON1 
cells, sunitinib alone induced LMP, which was further increased by addition of CQ or upon 
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knockdown of LAMP2. In QGP1 only the combination of sunitinib and a high concentration of 
CQ induced LMP, while single treatments did not (Supplementary Fig. S7A). This different 
susceptibility towards LMP seems to correlate with autophagic flux. Indeed, when autophagic 
flux upon sunitinib treatment is assessed by calculating the difference with and without CQ or 
BafA1, the two cell lines showed different results. In both cell lines autophagic flux upon 
sunitinib increased if LC3B-II levels were measured upon CQ treatment, while the flux was 
reduced when measured upon BafA1 treatment (Supplementary Fig. S7B). Interestingly, in 
QGP1 cells a higher concentration of CQ than the one used in BON1 increased flux, while a 
lower concentration of CQ also reduced the flux. (Supplementary Fig. S7C). These data 
suggest that BON1 cells are more susceptible than QGP1 towards LMP and show sunitinib-
induced autophagy, while in QGP1 cells sunitinib rather blocked autophagy. Indeed, a recent 
study showed that sunitinib has a dual, concentration-dependent effect on autophagy in 
BON1 cells and that the threshold concentration differs between cell lines (53). This 
difference between BON1 and QGP1 cell lines might be due to the different levels of LAMP2 
which influence lysosomal stability and lysosomal membrane permeabilitation (14). Indeed, 
our data showed that LAMP2 knockdown sensitized both cell lines toward sunitinib or CQ 
treatment. Similarly, LAMP1 or LAMP2 knockdown sensitized osteosarcoma cells towards 
siramesine, a lysosomotropic drug (14). 
Our in vitro data suggest that sunitinib has a dual effect on autophagy by both blocking and 
inducing autophagy. We propose that the determining factor for the net effect of inhibition 
and induction is lysosome stability, with lysosome instability favoring cell death. Of note, in 
this context CQ and LAMP2 knockdown, which block autophagy, also contribute to 
autophagy induction via their destabilizing effect on lysosomes. The effect of BafA1 on LMP 
seems to be controversial in our results as well as in the literature and is probably context-
dependent. In contrast to CQ, BafA1 does not accumulate in lysosomes but elevates the pH 
via inhibition of vacuolar ATPase (20), BafA1 treatment was shown to induce a release of 
cathepsin D from lysosomes followed by activation of caspase 3 (54). On the other hand, 
pre-treatment with BafA1 can limit LMP induced by another drug (40,42,55). Interestingly, 
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BafA1 could revert sunitinib resistance resulting from lysosomal sequestration in renal and 
colon cancer cell lines (11).  
Based on our data, we propose that sunitinib accumulates in lysosomes and induces LMP. 
Autophagy is upregulated for clearance of damaged lysosomes, leading to recovery of the 
cells, therefore playing a pro-survival role. Combination of sunitinib with CQ or shLAMP2 
leads to a higher destabilization of lysosomes and increased LMP, which is associated with 
apoptosis-dependent cell death (Fig. 6). 
Lysosomes are an attractive therapeutic target because cancer cell lysosomes are less 
stable and more prone to permeabilization (13). Many drugs approved for other diseases 
target lysosomes. Due to this property they might be exploited also as anti-cancer 
therapeutics (15). CQ, approved for treatment of malaria, is already tested in several clinical 
trials in combination with various anticancer treatments. In phase I clinical trials 
hydroxychloroquine (HCQ) led to a significant anti-tumor effect in combination with other 
therapeutics (36,37). A clinical phase I trial is ongoing for the combination of sunitinib and 
HCQ in advanced solid tumors that did not respond to chemotherapy (NCT00813423). Our 
study strongly supports the rationale of this combination for treatment of PanNET patients 
and their inclusion in such clinical trials.  
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Figure 1: Sunitinib modulates autophagy in PanNET cell lines and primary cells and 
combination with autophagy inhibition reduces viability and recovery  
A. Representative immunoblot for LC3B in BON1 and QGP1 cells upon 24h sunitinib (10μM), 
24h CQ (20μM in BON1, 50μM in QGP1), 5.5h BafA1 (200nM). LC3B-II levels were 
normalized to GAPDH or total protein, n≥4. B. Autophagic flux in BON1 and QGP1 cells 
calculated from percentage of proteolysis in long-lived protein degradation assay (treatment 
with BafA1 – treatment without BafA1), n=4. C. Immunoblots for LC3B in primary cells 
isolated from PanNET patients I and II upon 7h sunitinib (10μM), 7h CQ (20μM), 2h BafA1 
(200nM). LC3B-II levels were normalized to total protein and are indicated below the 
corresponding LC3B-II immunoblot, n=1. D. Viability of BON1 and QGP1 cells upon 
treatment. MTT assay was performed after 72h treatment with sunitinib (10μM), CQ (BON1 
20μM, QGP1 50μM), BafA1 (20nM) and values were normalized to control, n≥2. E. Viability 
of primary cells isolated from PanNET patients I and II upon treatment. ATPlite assay was 
performed after 48h treatments with indicated concentrations of CQ and sunitinib and values 
were normalized to control, n=1, error bars show technical replicates. F. Representative 
picture and quantification of clonogenic assay in BON1 cells. The image shows triplicates for 
each treatment of one representative experiment. Colonies were fixed and stained after two 
weeks without treatment and colony numbers were normalized to control, n≥3. Statistical 
analysis was performed using unpaired t-test, * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001. 
Figure 2: Significant anti-tumor effect in vivo upon combination treatment  
A. Graphic representation of the mouse treatment and macroscopically assessed tumor 
volume and number in Rip1Tag2 mice at 10 weeks of age and after three weeks of daily 
treatment with vehicle, CQ, sunitinib or sunitinib + CQ (10 weeks n=10, vehicle n=13, CQ 
n=12, sunitinib n=12, sunitinib + CQ n=12), unpaired t-test. B. Immunohistochemical staining 
for the proliferation marker Ki67. Percentage of Ki67 positive cells was estimated in 3-14 
tumors >1mm per mouse as shown in representative pictures with corresponding percentage 
on October 29, 2018. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 20, 2017; DOI: 10.1158/1535-7163.MCT-17-0136 
23 
 
of positive cells. C. Quantification of Ki67 staining. The graph shows the mean percentage of 
positive cells per mouse (vehicle n=13, CQ n=12, sunitinib n=12, sunitinib + CQ n=12), 
unpaired t-test. D. Quantification of percentage of necrosis determined on H&E staining 
(vehicle n=13, CQ n=12, sunitinib n=12, sunitinib + CQ n=12), unpaired t-test. E. 
Quantification of number of TUNEL-positive cells/mm2 as determined in one high-power field 
per mouse (vehicle n=13, CQ n=12, sunitinib n=12, sunitinib + CQ n=12). F. 
Immunohistochemical staining for LC3B. Classification of each mouse in LC3B punctae high 
or low based on abundance of dot staining as shown in representative pictures (LC3B 
punctae low: no dots in most of the tumors, LC3B punctae high: dots in most of the tumors). 
The graph presents the percentage of mice with LC3B high/low punctate staining (vehicle 
n=13, CQ n=12, sunitinib n=12, sunitinib + CQ n=12), Fisher’s exact test. * p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001. 
Figure 3: Sunitinib treatment of shATG5 and shATG7 cells only partially phenocopies 
combination with chloroquine  
A. Viability of BON1 shControl, shATG5 and shATG7 cells upon treatment. MTT assay was 
performed after 72h treatment with sunitinib (10μM), CQ (20μM) and values were normalized 
to the respective DMSO control, n≥3. B. Representative pictures of clonogenic assay in 
BON1 shControl, shATG5 and shATG7 cells. Colonies were fixed and stained after two 
weeks without treatment. Triplicates of one representative experiment are shown for each 
treatment. C. Clonogenic assay in BON1 shControl, shATG5 and shATG7 cells. Colony 
numbers were normalized to the respective DMSO control, n≥3 D. Representative 
immunoblot for ATG5, ATG7, cleaved caspase 3 and cleaved PARP in BON1 shControl, 
shATG5 and shATG7 cells after 24h treatment with sunitinib (10μM), CQ (20μM), BafA1 
(20nM), n=3. E. Representative immunoblot for ATG5, ATG7, cleaved caspase 3 and 
cleaved PARP in QGP1 shControl, shATG5 and shATG7 cells after 24h treatment with 
sunitinib (10μM), CQ (50μM), BafA1 (50nM), n=3.Statistical analysis was performed using 
unpaired t-test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 4: Sunitinib treatment of shLAMP2 cells phenocopies combination with 
chloroquine  
A. Viability of BON1 shControl, shLAMP2-291 and shLAMP2-561 cells upon treatment. MTT 
assay was performed after 72h treatment with sunitinib (10μM), CQ (20μM) and values were 
normalized to the respective DMSO control, n≥3. B. Representative pictures of clonogenic 
assay in BON1 shControl, shLAMP2-291 and shLAMP2-561 cells. Colonies were fixed and 
stained after two weeks without treatment. Triplicates of one representative experiment are 
shown for each treatment. C. Clonogenic assay in BON1 shControl, shLAMP2-291 and 
shLAMP2-561 cells. Colony numbers were normalized to the respective DMSO control, n≥3 
D.  Representative immunoblot for LAMP2, cleaved caspase 3 and cleaved PARP in BON1 
shControl, shLAMP2-291 and shLAMP2-561 after 24h treatment with sunitinib (10μM), CQ 
(20μM), BafA1 (20nM), n=3. E. Representative immunoblot for LAMP2, cleaved caspase 3 
and cleaved PARP in QGP1 shControl, shLAMP2-291 and shLAMP2-561 after 24h 
treatment with sunitinib (10μM), CQ (50μM), n=3. Statistical analysis was performed using 
unpaired t-test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
Figure 5: Effect of combination treatment depends on lysosome stability and is 
mediated by lysosomal membrane permeabilization  
A. Representative immunoblots for LAMP2 in BON1 and QGP1 shControl, shLAMP2-291 
and shLAMP2-561 cells, n>3. B. Viability of BON1 shControl, shLAMP2-291 and shLAMP2-
561 cells upon treatment. MTT assay was performed after 72h treatment with increasing 
concentrations of CQ (20μM, 50μM, 100μM) and values were normalized to the respective 
vehicle control, n=3. C. Viability of QGP1 shControl, shLAMP2-291 and shLAMP2-561 cells 
upon treatment. MTT assay was performed after 72h treatment with increasing 
concentrations of CQ (20μM, 50μM, 100μM) and values were normalized to the respective 
vehicle control, n=3. D. Representative images showing the co-localization of the sunitinib-
autofluorescence (72h, 10μM) in the FITC channel and Lysotracker Red staining lysosomes 
(1h, 100nM) in the Cy3 channel. Scale bar 10µm, applies to all images.  E. Representative 
immunofluorescent picture of a LMP-positive BON1 cell showing galectin 3 dotted staining 
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and a negative cell without dotted galectin 3 staining upon 48h sunitinib + CQ treatment. 
Nuclei were stained with DAPI. Scale bar 20µm. F. LMP in BON1 cells upon treatment. 
Percentage of galectin 3 positive cells upon 24h and 48h treatment with sunitinib (10μM) and 
CQ (20μM) was calculated from 500-600 counted cells in randomly chosen fields, n=5. G. 
LMP in BON1 shControl, shLAMP2-291 and shLAMP2-561 cells upon treatment. Percentage 
of galectin 3 positive cells upon 24h and 48h treatment with sunitinib (10μM) and CQ (20μM) 
was calculated from 500-600 counted cells in randomly chosen fields, n≥5. Statistical 
analysis was performed using unpaired t-test, * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001. 
Figure 6: Proposed model of sunitinib and combination effect 
Sunitinib accumulates in lysosomes and induces autophagy. Autophagy enables recovery of 
the cells, therefore playing a pro-survival role. If autophagy is blocked via knockdown of 
ATG5 or ATG7 in combination with sunitinib, reduced recovery is observed. Upon 
combination of sunitinib with CQ or LAMP2 knockdown, both combinations collaborate to a 
higher destabilization of lysosomes in addition to reduced recovery, leading to apoptosis-
dependent cell death. 
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